Novartis Campus opening further
Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel Area is the first major external organization to already have offices on the Novartis Campus.
The biotech and pharma group Novartis has announced that they are opening their campus further for the public. In a first phase, starting this year, Novartis opens the premises for startups, incubators, institutes, companies and partners. With this step, the company wants to strengthen collaboration between leading and emerging players in the fields of research, development and technology.
The first partner already on the campus is the Switzerland Innovation Park Basel Area that operates offices on the campus. Opened in mid-2020, the site of Switzerland Innovation Park Basel Area, which is run by Basel Area Business & Innovation, supports startups and established companies from the fields of digital health and personalized medicine. The objective is to establish a closeness between startups and the scientists from Novartis.
The second step will start late in 2022, when the Novartis Campus will be opened to the public during working hours. The Novartis Pavilion, which is currently under construction, will be a first visible milestone for the opening.
“By inviting the public to engage in dialogue in the Novartis Pavillon, we are strengthening our commitment and interaction with society as a whole and especially with the local community. We want to create transparency by encouraging exchanges and learning from each other,” said Jörg Reinhardt, Chairman of the Board of Directors. Novartis is confident the Campus opening will boost Basel as a business location and Switzerland in general.
Share this article
You may also be interested in
RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...Read More
Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm...Read More
Learn more about our AI Program for SMEsRead More